ARTICLE
31 October 2022

The IP Podcast – Season 2 Ep. 4: Repurposed Drugs And Skinny Labelling

D
Dehns
Contributor
Dehns logo
Dehns is a leading European firm of specialist patent and trade mark attorneys, with more than 200 people across seven offices, and with an internationally renowned reputation.
In this episode of The IP Podcast, Senior Associate Daniel Rowe discusses a topic relating to the biotechnology and pharma industries: repurposed drugs and skinny labelling.
UK Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

In this episode of The IP Podcast, Senior Associate Daniel Rowe discusses a topic relating to the biotechnology and pharma industries: repurposed drugs and skinny labelling.

Tune in to hear Dan answer:

  • What are repurposed drugs and why are they important?
  • Can repurposed drugs be patent protected even though the patent covering the original drug may have expired?
  • What is a skinny label?

All these questions and more, answered in less than 20 minutes!

For a deeper dive into Skinny Labelling and Repurposed Drugs, read Dan's latest article on the subject, where he examines the current situation inside and outside the EU and looks at good practice for generic companies and opportunities for innovator companies.

CLICK HERE TO LISTEN ON SPOTIFY

CLICK HERE TO LISTEN ON APPLE PODCASTS

'The IP Podcast' can also be found on Spotify, iTunes and Google Podcasts. Search for "Dehns IP" and subscribe to make sure you never miss an episode!

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
31 October 2022

The IP Podcast – Season 2 Ep. 4: Repurposed Drugs And Skinny Labelling

UK Food, Drugs, Healthcare, Life Sciences
Contributor
Dehns logo
Dehns is a leading European firm of specialist patent and trade mark attorneys, with more than 200 people across seven offices, and with an internationally renowned reputation.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More